P1.225. The Impact of Metformin Use During Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A Propensity Score-Matched Nationwide Study

Clicks: 22
ID: 325995
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #101 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – long term outcomes Background Our previous study suggested an association between metformin use and complete response rates in esophageal cancer patients undergoing neoadjuvant concurrent chemoradiotherapy (CCRT). This study aims to evaluate the impact of metformin use during neoadjuvant CCRT on overall survival (OS) and cancer-specific survival (CSS) in esophageal cancer patients undergoing surgery, using a nationwide database. Methods We utilized the National Health Insurance Research Database to analyze patients diagnosed with esophageal cancer between January 2010 and December 2022. The index date was defined as the initiation of neoadjuvant therapy, with follow-up extending until December 2022. After propensity score matching (PSM), Cox regression analyses were performed to identify risk factors for survival outcomes, including OS and CSS. Results A total of 2,345 patients who underwent neoadjuvant CCRT followed by surgery were included, with 568 patients remaining after PSM. Metformin use was associated with a higher risk of all-cause mortality (HR: 1.28, 95% CI: 1.05–1.57, p = 0.014). The 5-year OS rates were 23.4% in the metformin group and 31.1% in the non-metformin group (p = 0.018). However, metformin use was not significantly associated with CSS, with 5-year CSS rates of 34.7% and 41.0% in the metformin and non-metformin groups, respectively (p = 0.140). Conclusion This is the first nationwide database analysis evaluating the impact of metformin use during CCRT on OS and CSS in esophageal cancer patients. Metformin use was associated with lower OS but did not significantly affect CSS. Further study should be needed.
Reference Key
openalex_W7203977665 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Taeyoung Yun, Chang Hyun Kang, Ji Hyeon Park, Kwon Jung Na, Samina Park, Hyun Joo Lee, In Kyu Park, Young Tae Kim
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.373
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.373/70761273/doag077.373.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.